Barclays Downgrades Nuvalent, Inc. to Hold
Barclays has lowered its rating for Nuvalent, Inc. to hold, with a $124 price target.
Key Points
- Barclays downgraded Nuvalent, Inc. (NasdaqGS: NUVL) to a hold rating with a $124 price target on June 10, 2026.
- Shares of Nuvalent traded at $123.25, with a market cap of $9.75 billion, a forward P/E of -29.83, and a beta of 1.153.
- Institutions like JPMorgan Chase & Co increased their holdings in Nuvalent, while others like FMR LLC reduced their positions.
On June 10, 2026, Barclays analyst Etzer Darout downgraded Nuvalent, Inc. (NasdaqGS: NUVL) to a hold rating, setting a price target of $124. This move comes as the stock trades near $123.25, reflecting a cautious stance on the clinical-stage biopharmaceutical company.
Other Institutional Activity in Nuvalent
Several institutional investors have made notable changes to their holdings in Nuvalent. FMR LLC reduced its position by 1,577,925 shares, ending with 9,274,959 shares valued at approximately $950.2 million. Conversely, JPMorgan Chase & Co increased its stake by 883,098 shares, bringing its total to 3,088,349 shares worth about $298.7 million. Paradigm Biocapital Advisors LP also added 55,000 shares, holding 5,324,433 shares valued at $545.5 million.
Nuvalent, Inc. Stock Snapshot
Shares of Nuvalent, Inc. are trading at $123.25, near their 52-week high of $123.62. The company has a market capitalization of $9.75 billion and a forward P/E ratio of -29.83, indicating it is not profitable. With a beta of 1.153, the stock shows moderate volatility. Its 50-day moving average is $104.10, while the 200-day moving average stands at $98.73. The company's current ratio is 16.137, suggesting strong liquidity.
Recent Earnings
Nuvalent, Inc. reported an EPS of -$6.06, with no net margin, reflecting ongoing development costs. The company's return on equity is -41.19%. Investors are looking ahead to the next earnings release scheduled for August 6, 2026.
Insider Buying and Selling at Nuvalent, Inc.
Recent insider transactions at Nuvalent include Chief Development Officer Darlene Noci selling 20,000 shares on June 9, 2026, at an average price of $122.81 under a planned sale. On the same day, she also bought 20,000 shares at $9.59. President and CEO James Richard Porter sold 30,000 shares on June 8, 2026, at $88.53 in a planned transaction, while also purchasing 30,000 shares at $18.93.
Analysts Set New Price Targets
On June 10, 2026, several firms, including TD Cowen, UBS, and Guggenheim, joined Barclays in downgrading Nuvalent to a hold rating, each setting a price target of $124. The consensus among 16 analysts is a hold rating, with a mean target price of $128.13.
About Nuvalent, Inc.
Nuvalent, Inc., headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focusing on developing therapies for cancer patients. The company is working on several innovative treatments, including Zidesamtinib, Neladalkib, and NVL-330, which are in various stages of clinical trials. Led by CEO Dr. James R. Porter, the company employs 234 people and has formed a strategic partnership with Guardant Health, Inc. to advance companion diagnostic therapies.
Bottom Line
Barclays' downgrade of Nuvalent, Inc. to a hold rating reflects a cautious outlook amid the company's ongoing development efforts and financial performance. As a clinical-stage biotech firm, Nuvalent's stock is closely watched by investors for its potential in addressing cancer treatment challenges. Keep in mind that analyst ratings and price targets are based on available data and may change as new information emerges.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.